Research Analysts Set Expectations for PolyPid Q2 Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Investment analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for PolyPid in a report released on Thursday, May 14th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.38) per share for the quarter, up from their previous forecast of ($0.47). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for PolyPid’s Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($1.64) EPS, FY2027 earnings at ($0.71) EPS and FY2028 earnings at $0.10 EPS.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.12.

Several other research analysts have also recently commented on PYPD. Weiss Ratings cut PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $12.25.

PolyPid Price Performance

PYPD stock opened at $4.73 on Tuesday. The business has a 50-day moving average of $4.40 and a 200-day moving average of $4.25. PolyPid has a fifty-two week low of $2.44 and a fifty-two week high of $5.12. The stock has a market capitalization of $90.25 million, a P/E ratio of -2.48 and a beta of 1.41.

Institutional Investors Weigh In On PolyPid

Institutional investors have recently made changes to their positions in the stock. AIGH Capital Management LLC grew its position in shares of PolyPid by 26.1% in the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock valued at $5,828,000 after buying an additional 277,844 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of PolyPid in the 4th quarter valued at about $451,000. XTX Topco Ltd grew its position in shares of PolyPid by 50.0% in the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after buying an additional 10,888 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of PolyPid in the 4th quarter valued at about $66,000. Finally, HighTower Advisors LLC bought a new stake in shares of PolyPid in the 4th quarter valued at about $44,000. Institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.